{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:40:13Z","timestamp":1772077213260,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1124\/jpet.110.173641","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T01:46:30Z","timestamp":1294191990000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor"],"prefix":"10.1016","volume":"337","author":[{"given":"Anthony T.","family":"Nials","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy J.","family":"Tralau-Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele H.","family":"Gascoigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas I.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa E.","family":"Ranshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.173641_bib1","first-page":"A690","article-title":"ELB526, a new selective PDE4 inhibitor with a large safety margin and potent activity in animal models of asthma","volume":"175","author":"Bebo","year":"2007","journal-title":"Am J Resp Crit Care"},{"key":"10.1124\/jpet.110.173641_bib2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1183\/09031936.00048506","article-title":"Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model","volume":"28","author":"Birrell","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.110.173641_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1096\/fj.04-2691fje","article-title":"Resevatrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-\u03baB-independent mechanism","volume":"19","author":"Birrell","year":"2005","journal-title":"FASEB J"},{"key":"10.1124\/jpet.110.173641_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1517\/13543784.15.9.1105","article-title":"Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease","volume":"15","author":"Boswell-Smith","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.110.173641_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0022-3565(24)29538-0","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173641_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"Am J Crit Care Med"},{"key":"10.1124\/jpet.110.173641_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2007.05.074","article-title":"Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late-phase airflow obstruction in Brown Norway rats","volume":"571","author":"Chapman","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejphar.2010.06.054","article-title":"Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration","volume":"643","author":"Chapman","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1358\/dot.2005.41.10.920428","article-title":"Roflumilast: a selective phosphodiesterase 4 inhibitor","volume":"41","author":"Christie","year":"2005","journal-title":"Drugs Today"},{"key":"10.1124\/jpet.110.173641_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2006.10.018","article-title":"Altered gene expression in rat mesenteric tissue following in vivo exposure to phosphodiesterase 4 inhibitors","volume":"218","author":"Dagu\u00e8s","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib11","first-page":"91","article-title":"The anti-inflammatory and emetogenic properties of phosphodiesterase (PDE) inhibitors in conscious ferrets","volume":"116","author":"Dale","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2006.07.002","article-title":"Effects of ciclamilast, a new PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma","volume":"547","author":"Deng","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1164\/ajrccm\/142.2.434","article-title":"Mucosal inflammation in asthma","volume":"142","author":"Djukanovi\u0107","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/jpet.110.173641_bib14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1164\/ajrccm.164.6.2012139","article-title":"Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled budesonide","volume":"164","author":"Ferreira","year":"2001","journal-title":"Am J Resp Crit Care Med"},{"issue":"Suppl 33","key":"10.1124\/jpet.110.173641_bib15","first-page":"36","article-title":"The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor, Bay 19\u20138004, in guinea-pig antigen challenge and ferret emesis models","volume":"18","author":"Fitzgerald","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.110.173641_bib16","first-page":"A486","article-title":"The inhaled PDE4 inhibitor Tofimilast does not inhibit airway responses to allergen and histamine","volume":"175","author":"Fregonese","year":"2007","journal-title":"Am J Resp Crit Care"},{"key":"10.1124\/jpet.110.173641_bib17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","article-title":"Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease","volume":"10","author":"Giembycz","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.110.173641_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/bjp.2008.297","article-title":"Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?","volume":"155","author":"Giembycz","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib19","first-page":"495","article-title":"Is PDE4 too difficult a drug target?","volume":"11","author":"Higgs","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1124\/jpet.110.173641_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(94)90931-8","article-title":"Increased nitric oxide in exhaled air of asthmatic patients","volume":"343","author":"Kharitonov","year":"1994","journal-title":"Lancet"},{"key":"10.1124\/jpet.110.173641_bib21","article-title":"In vivo characterization of GSK256066, an exceptionally high affinity and selective PDE4 inhibitor suitable for topical administration","volume":"179","author":"Knowles","year":"2009","journal-title":"Am J Rev Crit Care Med"},{"key":"10.1124\/jpet.110.173641_bib22","article-title":"In vitro characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for administration by inhalation","volume":"179","author":"Knowles","year":"2009","journal-title":"Am J Rev Crit Care Med"},{"key":"10.1124\/jpet.110.173641_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1124\/jpet.103.053942","article-title":"In vivo efficacy in airway disease models of N-(3,5-dichloro-pyrid-4-yl)-{1-(4-fluorobenzyl)-5-hyroxy-indole-3-yl}-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration","volume":"307","author":"Kuss","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173641_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/ajrccm\/141.3.540","article-title":"The effect of endotoxin inhalation on airway responsiveness and cellular influx in rats","volume":"141","author":"Pauwels","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1124\/jpet.110.173641_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0079-6468(08)00202-6","article-title":"PDE4 inhibitors- a review of the current field","volume":"47","author":"Press","year":"2009","journal-title":"Prog Med Chem"},{"key":"10.1124\/jpet.110.173641_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1465-9921-11-26","article-title":"The unhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma","volume":"11","author":"Singh","year":"2010","journal-title":"Respir Res"},{"key":"10.1124\/jpet.110.173641_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjp.2008.307","article-title":"PDE4 inhibitors: current status","volume":"155","author":"Spina","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.173641_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase enzymes: molecular targets for novel antiasthma drugs","volume":"157","author":"Torphy","year":"1998","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1124\/jpet.110.173641_bib29","article-title":"GSK256066, an exceptionally high-affinity and selective inhibitor of PDE4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization","author":"Tralau-Stewart","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173641_bib30","first-page":"A927","article-title":"UK-500,001 a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNF alpha, MIP1beta and LTB4 release from native human blood cells","volume":"175","author":"Trevethick","year":"2007","journal-title":"Am J Respir Crit Care"},{"key":"10.1124\/jpet.110.173641_bib31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0022-3565(24)37892-9","article-title":"Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB207499 (Ariflo) in the guinea pig","volume":"287","author":"Underwood","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173641_bib32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1183\/09031936.00068908","article-title":"A controlled trial of 6 weeks\u2019 treatment with a novel, inhaled phosphodiesterase type 4 inhibitor in COPD","volume":"33","author":"Vestbo","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.110.173641_bib33","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1016\/j.bmcl.2009.04.012","article-title":"Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration","volume":"19","author":"Woodrow","year":"2009","journal-title":"Bioorg Med Chem Lett"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524463106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524463106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.173641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:27:37Z","timestamp":1740018457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524463106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0022356524463106"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.173641","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.173641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}